Yes, is there anything particular you’d like to note about the design of the combination vaccine study and the formulations because I’m also excited unabashedly about a combination of putting in the Respiratory Syncytial Virus work that you’ve done, which has also achieved a Phase 3 stage?
Greg Glenn
Yes, I think it lays the groundwork for where we are – we’re committed. So this, I mean, to be the nerd here. These are Type 1 fusion proteins. We hit good. Yes, you’re the nerd. We know they work by similar mechanism. And this year, this past year has provided a fantastic proof-of-concept for the technology. And if you had to hone in on a topic, it’s the Type 1 fusion protein infections like RSV that are driven by these proteins. And so we know that we can return to these topics. I think, where RSV protein program struggled, had a lot to do with design, the inability to, go design the clinical trials and go with sort of the longer, bigger trials. I think we’re in a very different situation day, lots of learning from our clinical experience, and we are very eager to get back into the RSV business too.